| Biomarker ID | 1155 |
| PMID | 23826159 |
| Year | 2013 |
| Biomarker | LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: [OR: 1.42 (95% CI: 1.28–1.60)] Multivariate Analysis: [OR: 1.36 (95% CI: 1.16–1.60) |
| Effect on Pathways | Pathways include (NFIB): RNA polymerase III abortive and retractive initiation, HNF3A pathway, RNA polymerase I, RNA polymerase III, and mitochondrial transcription, Transcription, BDNF signaling pathway. Pathways include (UBE2C): Inactivation of APC/C via direct inhibition of the APC/C complex, Autodegradation of Cdh1 by Cdh1-APC/C, APC/C-mediated degradation of cell cycle proteins, Cell cycle checkpoints, Interleukin-1 signaling pathway |
| Experiment | Metastasis Vs No Metastasis |
| Type of Biomarker | Prognostic |
| Cohort | In training Set there were 359 samples - 129 with Metastasis and in the Validation set there were 186 samples - 63 with Metastasis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | Training: 0.90; Validation: 0.75 |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |